This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rees, C. Articles by Judson, I. Search for Related Content PubMed PubMed Citation Articles by Rees, C. Articles by Judson, I.

Phase I Trial of ZD9331, a Nonpolyglutamatable Thymidylate Synthase Inhibitor, Given as a 5-Day Continuous Infusion to Patients with Refractory Solid Malignancies

Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom [C. R., P. B., J. M. T., F. M., A. J., I. J.]; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom [R. S.]; and AstraZeneca, Wilmington, Delaware [E. D.]

Purpose: This dose-escalating study investigated the toxicity, pharmacokinetics, and efficacy of the novel direct-acting antifolate ZD9331, given as a 5-day i.v. infusion every 3 weeks.

Experimental Design: Forty-five patients with refractory solid malignancies received ZD9331, which was escalated from 0.125 mg/m²/day.

Results: Dose-limiting grade 4 thrombocytopenia occurred in 3 of 6 patients treated at 8 mg/m²/day; other drug-related toxicities, across dose levels, included skin and gastrointestinal toxicity, lethargy, and asymptomatic, reversible, elevated transaminases. The maximum plasma concentration and area under the curve increased with dose. Clearance was dose-dependent and predominantly renal. At doses ≥2.4 mg/m²/day, plasma 2'-deoxyuridine levels were elevated consistently indicating inhibition of thymidylate synthase. Two patients had a partial response (breast, 1 patient; ovarian, 1 patient), and 10 patients had stable disease.

Conclusion: The maximum tolerated dose was defined as 6 mg/m²/day, and the toxicity profile for this regimen was considered acceptable and manageable. Administration of ZD9331 lead to elevation of 2'-deoxyuridine levels, signifying thymidylate synthase inhibition, and evidence of antitumor activity was observed.

This article has been cited by other articles:

				D. S. Theti and A. L. Jackman The Role of {alpha}-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs Clin. Cancer Res., February 1, 2004; 10(3): 1080 - 1089. [Abstract] [Full Text] [PDF]